Express Scripts bars 48 drugs for 2019, hitting AbbVie, Gilead, Boehringer and more It’s that time of year again—the time when lead pharmacy benefits manager Express Scripts ignites pharma’s ire […]
With patisiran launch in its sights, Alnylam plots a major hiring spree Alnylam’s first drug approval could come any day now, and the company is bulking up to get ready—in […]
FDA notes Paratek antibiotic’s noninferiority as it heads to AdComm vote Paratek Pharmaceuticals’ first drug, and the first in a new class of broad-spectrum antibiotics called aminomethylcyclines, has shown to […]
Akouos raises M to take hearing loss gene therapy into humans Akouos has raised $50 million to take a gene therapy treatment for hearing loss into the clinic. The Boston-based […]
Ironwood abandons deal with AstraZeneca for lesinurad, once hoped to be a gout blockbuster Ironwood Pharmaceuticals has decided to walk away from its 2016 deal to license AstraZeneca’s billion-dollar gout […]
Ironwood dumps AstraZeneca gout drug Zurampic—and lays off 125 in the process Zurampic, a drug AstraZeneca once laid out more than $1 billion to get its hands on, has wound […]
Acorda inks Ampyra generic settlements as it waits for patent appeal news Late last month, a court refused to block copies of Acorda’s Ampyra leading up to a patent appeal […]
Mayo Clinic pinpoints genes that raise the risk of triple-negative breast cancer The ability to identify women who face the highest risk of triple-negative breast cancer could save lives, but […]
Janssen, Bayer to close South Korean plants due to limited demand Janssen and Bayer are joining a long list of pharma companies closing their manufacturing facilities in South Korea. And […]
Allergan preludes major selloffs with 0M Almirall dermatology sale Allergan, which is shopping assets to help turn its stock price around, has taken its first small step into selloff land. […]